PharmaCorp Rx Inc.
PCRX.V
TSX
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -11.16% | 288.12% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -11.16% | 288.12% | |||
| Cost of Revenue | -14.83% | 285.87% | |||
| Gross Profit | -5.16% | 291.73% | |||
| SG&A Expenses | 5.18% | -24.96% | |||
| Depreciation & Amortization | -4.53% | 146.04% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -8.79% | 77.36% | |||
| Operating Income | -37.87% | 131.29% | |||
| Income Before Tax | -42.69% | 161.46% | |||
| Income Tax Expenses | 198.17% | -12,850.00% | |||
| Earnings from Continuing Operations | -65.71% | 172.08% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -133.33% | 1,884.62% | |||
| Net Income | -68.92% | 175.81% | |||
| EBIT | -37.87% | 131.29% | |||
| EBITDA | -27.26% | 148.25% | |||
| EPS Basic | -67.39% | 173.02% | |||
| Normalized Basic EPS | -50.00% | 166.67% | |||
| EPS Diluted | -67.39% | 173.02% | |||
| Normalized Diluted EPS | -50.00% | 166.67% | |||
| Average Basic Shares Outstanding | -1.91% | 3.87% | |||
| Average Diluted Shares Outstanding | -1.91% | 3.87% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||